帕博西利布
转移性乳腺癌
医学
来曲唑
肿瘤科
乳腺癌
养生
内科学
化疗
癌症
三苯氧胺
作者
Laura A. Huppert,Hope S. Rugo
标识
DOI:10.1158/1078-0432.ccr-23-1909
摘要
A recent phase Ib/II trial evaluated the combination of tucatinib, letrozole, and palbociclib in patients with HR+/HER2+ metastatic breast cancer, demonstrating a manageable safety profile and encouraging efficacy data. An all-oral, chemotherapy-free regimen is an appealing strategy, and could be a possible maintenance or primary therapy option in select patients. See related article by Shagisultanova et al., p. 5021.
科研通智能强力驱动
Strongly Powered by AbleSci AI